Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW27011 combination therapy in CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
CTR20260013Phase 2Active
- Sponsor
- Sinovent
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ASP546C in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sinovent. Started Feb 2026; status: active.
02
Drugs
ASP546C
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260013.